AI주식인사이트AI Stock Insight
C

에스티큐브

052020KOSDAQ기계장비 및 관련 물품 도매업

43.5 / 100

Reference Date: 2026-04-13

Financial Score8.0 / 40
News Sentiment17.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Declined 14.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

STCube operates in biopharmaceuticals and cosmetics distribution, with its innovative immunotherapy drug 'Nelmastobart' showing promising clinical results. The company's own brand 'Scenearth' is expanding globally, while industrial lens module distribution contributes significantly to revenue.

Number of Employees

16people

Average Salary

66.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 10.904.0Point
PBR
14.61Industry Average 0.770.0Point

19.0x industry avg (risky)

ROE
-26.20Industry Average 3.030.0Point

Well below industry avg

Debt Ratio
19.56Industry Average 6.160.0Point

3.2x industry avg (risky)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲27.8% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.7% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -38.6% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 1Negative 0Average Sentiment Score 70

Detailed Momentum

52-week position6.0Point

52w upper range (71%)

Current 15,500Won52-week high 19,51052-week low 5,580
1-month return1.0Point

1m -14.13% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral정기주주총회결과2026-03-26
  • Neutral사업보고서 (2025.12)2026-03-18
  • Neutral감사보고서제출2026-03-18